241 related articles for article (PubMed ID: 15161787)
1. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes.
Natali A; Baldeweg S; Toschi E; Capaldo B; Barbaro D; Gastaldelli A; Yudkin JS; Ferrannini E
Diabetes Care; 2004 Jun; 27(6):1349-57. PubMed ID: 15161787
[TBL] [Abstract][Full Text] [Related]
2. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.
Iozzo P; Hallsten K; Oikonen V; Virtanen KA; Parkkola R; Kemppainen J; Solin O; Lonnqvist F; Ferrannini E; Knuuti J; Nuutila P
Diabetes Care; 2003 Jul; 26(7):2069-74. PubMed ID: 12832315
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
[TBL] [Abstract][Full Text] [Related]
4. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
Fonseca V; Rosenstock J; Patwardhan R; Salzman A
JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
[TBL] [Abstract][Full Text] [Related]
5. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
[TBL] [Abstract][Full Text] [Related]
6. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
7. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
[TBL] [Abstract][Full Text] [Related]
8. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
[TBL] [Abstract][Full Text] [Related]
9. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients.
Poulsen MK; Henriksen JE; Hother-Nielsen O; Beck-Nielsen H
Diabetes Care; 2003 Dec; 26(12):3273-9. PubMed ID: 14633813
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.
Bailey CJ; Bagdonas A; Rubes J; McMorn SO; Donaldson J; Biswas N; Stewart MW
Clin Ther; 2005 Oct; 27(10):1548-61. PubMed ID: 16330291
[TBL] [Abstract][Full Text] [Related]
11. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.
Derosa G; Gaddi AV; Piccinni MN; Salvadeo S; Ciccarelli L; Fogari E; Ghelfi M; Ferrari I; Cicero AF
Diabetes Obes Metab; 2006 Mar; 8(2):197-205. PubMed ID: 16448524
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
Scott R; Loeys T; Davies MJ; Engel SS;
Diabetes Obes Metab; 2008 Sep; 10(10):959-69. PubMed ID: 18201203
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
Derosa G; Gaddi AV; Piccinni MN; Ciccarelli L; Salvadeo S; Peros E; Ghelfi M; Ferrari I; Cicero AF
Pharmacotherapy; 2005 May; 25(5):637-45. PubMed ID: 15899724
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients.
Negro R; Mangieri T; Dazzi D; Pezzarossa A; Hassan H
Diabetes Res Clin Pract; 2005 Oct; 70(1):20-5. PubMed ID: 16126119
[TBL] [Abstract][Full Text] [Related]
15. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
Fonseca V; Grunberger G; Gupta S; Shen S; Foley JE
Diabetes Care; 2003 Jun; 26(6):1685-90. PubMed ID: 12766094
[TBL] [Abstract][Full Text] [Related]
16. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control.
Pistrosch F; Passauer J; Fischer S; Fuecker K; Hanefeld M; Gross P
Diabetes Care; 2004 Feb; 27(2):484-90. PubMed ID: 14747233
[TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone RECORD study: glucose control outcomes at 18 months.
Home PD; Jones NP; Pocock SJ; Beck-Nielsen H; Gomis R; Hanefeld M; Komajda M; Curtis P;
Diabet Med; 2007 Jun; 24(6):626-34. PubMed ID: 17517066
[TBL] [Abstract][Full Text] [Related]
18. Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
Huang Z; Wan X; Liu J; Deng W; Chen A; Liu L; Liu J; Wei G; Li H; Fang D; Li Y
Diabetes Technol Ther; 2013 Oct; 15(10):859-69. PubMed ID: 23991629
[TBL] [Abstract][Full Text] [Related]
19. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.
Dailey GE; Noor MA; Park JS; Bruce S; Fiedorek FT
Am J Med; 2004 Feb; 116(4):223-9. PubMed ID: 14969649
[TBL] [Abstract][Full Text] [Related]
20. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
